RxDoctor Payments Data

Antonina Callahan, MD

Family Medicine · Bountiful, UTNPI 1699260620

Payments from drug & device makers

$5,504in general payments, 2019–2025

Across 341 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$804
  • Lilly USA, LLC$709
  • AstraZeneca$518
  • Boehringer Ingelheim$391
  • Novo Nordisk$390
  • GSK$359
  • plus $2K from 38 others
$500in research payments, 2019–2025

Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Lucid Diagnostics Inc.$500

What the payments were for

  • Food & beverage$5,504100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,504 in reported general payments places this provider in the 80th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$43,593
Medicare patients
77
Services billed
465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$37,281
EliquisApixaban15$24,829
JardianceEmpagliflozin15$23,201
JanumetSitagliptin Phos/Metformin Hcl12$20,364
MounjaroTirzepatide11$12,692
SynthroidLevothyroxine Sodium25$2,482
Levothyroxine Sodium164$2,225
Rosuvastatin Calcium119$1,687
Losartan Potassium170$1,618
Omeprazole86$1,441
Methylphenidate ErMethylphenidate Hcl15$1,408
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,183
Estradiol29$1,168
Bupropion XlBupropion Hcl33$1,102
Gabapentin51$919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$390$37,28130 claims
PfizerEliquis$185$24,82915 claims
Boehringer IngelheimJardiance$391$23,20115 claims
MerckJanumet$63$20,36412 claims
Lilly USA, LLCMounjaro$709$12,69211 claims
AbbVieSynthroid$804$2,48225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 928 family medicine providers in Utah.

Other family medicine in Bountiful

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →